β 2-Glycoprotein I: Evolution, structure and function

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 7, 2011, Pages 1275-1284

  De Groot, P G ^a   Meijers, J C M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

2 Glycoprotein I; Anti phospholipid syndrome; Innate immunity; LPS

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN; LIPOCORTIN 2; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VON WILLEBRAND FACTOR;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BINDING SITE; CARDIOVASCULAR RISK; COMPLEMENT SYSTEM; CRYSTAL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFECTION; INNATE IMMUNITY; MOLECULAR EVOLUTION; NONHUMAN; OXIDATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS;

BETA 2-GLYCOPROTEIN I; BIOLOGICAL EVOLUTION; HUMANS; IMMUNITY, INNATE; PROTEIN CONFORMATION;

EID: 79959834057     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04327.x     Document Type: Article

References (102)

1. Schultze HE, Heide K, Haupt H. Über ein bischer unbekanntes niedermolekularis β2-globulins des human serums. Naturwissenschaften 1961; 48: 719.
2. Haupt H, Schwick HG, Storiko K. On a hereditary beta-2-glycoprotein I deficiency. Humangenetik 1968; 5: 291-3.
3. Aǧar C, de Groot PG, Levels JH, Marquart JA, Meijers JC. Beta2-glycoprotein I is incorrectly named apolipoprotein H. J Thromb Haemost 2009; 7: 235-6.
4. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
5. Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) are directed not to cardiolipin but to a plasma cofactor. Lancet 1990; 335: 1544-7.
6. Miyakis S, Lockshin MD, Atsumi D, Branch W, Brey RL, Cervera R, Derksen RHWM, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the preliminary classification criteria for antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
7. Willems GM, Janssen MP, Pelsers MAL, Comfurius P, Galli M, Zwaal RFA, Bevers E. Role of divalency in the high affinity binding of cardiolipin antibody-β2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-42.
8. Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, Bossi F, Ziller F, Sblattero D, Meroni P, Tedesco F. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340-6.
9. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, Papalardo E, Vargas G, Deora AB, Wang M, Jacovina AT, Garcia-Latorre E, Reyes-Maldonado E, Hajjar KA, Pierangeli SS. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009; 114: 3074-83.
10. Ramesh S, Morrell CN, Tarango C, Thomas GD, Yuhanna YS, Girardi G, Herz J, Urbanus RT, de Groot PG, Thorpe PE, Salmon JE, Shaul PW, Mineo C. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest 2011; 121: 120-31.
11. Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT, Derksen RHWM, Pennings MTT, Papalardo E, Shilagard T, Vargas G, Hwang Y, de Groot PG, Pierangeli SS. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood 2011; 117: 1408-14.
12. Jankowski M, Vreys I, Wittevrongel C, Boon D, Vermylen J, Hoylaerts MF, Arnout J. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101: 157-62.
13. Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med 2011; 17: 317-29.
14. 2-glycoprotein I. Molecular cloning and mammalian expression of human beta 2-glycoprotein I cDNA. Proc Natl Acad Sci USA 1991; 81: 3640-4.
15. Kristensen T, Schousboe I, Boel E, Mulvihill EM, Hansen RR, Møller KB, Møller NP, Sottrup-Jensen L. Molecular cloning and mammalian expression of human beta 2-glycoprotein I cDNA. FEBS Lett 1991; 289: 183-6.
16. Bouma B, de Groot PG, van der Elsen JMH, Ravelli RBG, Schouten A, Simmelink MJA, Derksen RHWM, Kroon J, Gros P. Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-74.
17. Schwartzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R. Crystal structure of human β2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 6228-31.
18. de Planque MR, Kruijtzer JA, Liskamp RM, Marsh D, Greathouse DV, Koeppe RE 2nd, de Kruijff B, Killian JA. Different membrane anchoring positions of tryptophan and lysine in synthetic transmembrane alpha-helical peptides. J Biol Chem 1999; 274: 20839-46.
19. 2-glycoprotein I only after a conformational change. Blood 2006; 107: 1916-24.
20. Hammel M, Kriechbaum M, Gries A, Kostner GM, Laggner P, Prassl R. Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering. J Mol Biol 2002; 321: 85-97.
21. Kondo A, Miyamoto T, Yonekawa O, Giessing AM, Østerlund EC, Jensen ON. Glycopeptide profiling of beta-2-glycoprotein I by mass spectrometry reveals attenuated sialylation in patients with antiphospholipid syndrome. J Proteomics 2009; 73: 123-33.
22. Agar C, van Os GM, Mörgelin M, Sprenger RR, Marquart JA, Urbanus RT, Derksen RH, Meijers JC, de Groot PG. Beta2-Glycoprotein I can exist in two conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116: 1336-43.
23. 2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost 2006; 4: 1680-90.
24. Oppermann M, Manuelian T, Józsi M, Brandt E, Jokiranta TS, Heinen S, Meri S, Skerka C, Götze O, Zipfel PF. The C-terminus of complement regulator factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol 2006; 144: 342-52.
25. Okemefuna AI, Nan R, Gor J, Perkins SJ. Electrostatic interactions contribute to the folded-back conformation of wild type human factor H. J Mol Biol 2009; 391: 98-118.
26. Brighton TA, Dai YP, Hogg PJ, Chesterman CN. Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids. Biochem J 1999; 340: 59-67.
27. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Variability of anti-beta2 glycoprotein I antibodies measurements by commercial assays. Thromb Haemost 2005; 94: 665-72.
28. Giannakopoulos B, Mirarabshahi P, Krilis SA. New insights into the biology and pathobiology of beta2-glycoprotein I. Curr Rheumatol Rep 2011; 13: 90-5.
29. Ioannou Y, Zhang JY, Passam FH, Rahgozar S, Qi JC, Giannakopoulos B, Qi M, Yu P, Yu DM, Hogg PJ, Krilis SA. Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood 2010; 116: 1961-70.
30. Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC, Giannakopoulos B, Hughes WE, Hogg PJ, Krilis SA. Beta2-glycoprotein I is a substrate of thiol oxidoreductases. Blood 2010; 116: 1995-7.
31. Hogg PJ. Contribution of allosteric disulfide bonds to regulation of hemostasis. J Thromb Haemost 2009; 7 (Suppl. 1): 13-16.
32. Rioche M, Masseyeff R. Synthesis of plasma beta 2 glycoprotein I by human hepatoma cells in tissue culture. Biomedicine 1974; 21: 420-3.
33. 2-glycoprotein I in thrombotic disorders and in inflammation. Lupus 2006; 15: 87-93.
34. Vlachoyiannopoulos PG, Krilis SA, Hunt JE, Manoussakis MN, Moutsopoulos HM. Patients with anticardiolipin antibodies with and without antiphospholipid syndrome: their clinical features and beta 2-glycoprotein-I plasma levels. Eur J Clin Invest 1992; 22: 482-7.
35. Kamboh MI, Manzi S, Mehdi H, Fitzgerald S, Sanghera DK, Kuller LH, Atson CE. Genetic variation in apolipoprotein H (beta2-glycoprotein I) affects the occurrence of antiphospholipid antibodies and apolipoprotein H concentrations in systemic lupus erythematosus. Lupus 1999; 8: 742-50.
36. Suresh S, Demirci FY, Lefterov I, Kammerer CM, Ramsey-Goldman R, Manzi S, Kamboh MI. Functional and genetic characterization of the promoter region of apolipoprotein H (beta2-glycoprotein I). FEBS J 2010; 277: 951-63.
37. Mehdi H, Aston CE, Sanghera DK, Hamman RF, Kamboh MI. Genetic variation in the apolipoprotein H (beta2-glycoprotein I) gene affects plasma apolipoprotein H concentrations. Hum Genet 1999; 105: 63-71.
38. Mehdi H, Manzi S, Desai P, Chen Q, Nestlerode C, Bontempo F, Strom SC, Zarnegar R, Kamboh MI. A functional polymorphism at the transcriptional initiation site in beta2-glycoprotein I (apolipoprotein H) associated with reduced gene expression and lower plasma levels of beta2-glycoprotein I. Eur J Biochem 2003; 270: 230-8.
39. Iverson GM, Reddel S, Victoria EJ, Cockerill KA, Wang YX, Marti-Renom MA, Sali A, Marquis DM, Krilis SA, Linnik MD. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169: 7097-103.
40. De Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-5.
41. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56: 280-90.
42. de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, Ruffati A, Rozman B, Kveder T, de Moerloose P, Boehlen F, Rand J, Ulcova-Gallova Z, Mertens K, de Groot PG. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767-73.
43. Hattori N, Kuwana M, Kaburaki J, Mimori T, Ikeda Y, Kawakami Y. T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum 2000; 43: 65-75.
44. de Laat B, van Berkel M, Urbanus RT, Siregar B, de Groot PG, Gebbink M, Maas C. Immune responses against domain I of beta2-glycoprotein I are driven by conformational changes. Arthritis Rheum; in press.
45. Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 2008; 7: 272-7.
46. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999; 341: 2068-74.
47. Rose NR. Autoimmunity, infection and adjuvants. Lupus 2010; 19: 354-8.
48. Levine JS, Subang R, Nasr SH, Fournier S, Lajoie G, Wither J, Rauch J. Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J Immunol 2006; 177: 6504-16.
49. Aǧar C, de Groot PG, Mörgelin M, Monk SDDC, van Os GMA, Levels JHM, de Laat B, Urbanus RT, Herwald H, van der Poll T, Meijers JCM. β2-glycoprotein I: a novel component of innate immunity. Blood 2011; DOI: .
50. Buttari B, Profumo E, Mattei V, Siracusano A, Ortona E, Margutti P, Salvati B, Sorice M, Riganò R. Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response. Blood 2005; 106: 3880-7.
51. Morgan PE, Sturgess AD, Davies MJ. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2069-79.
52. Yasuda S, Atsumi T, Matsuura E, Kaihara K, Yamamoto D, Ichikawa K, Koike T. Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant. Arthritis Rheum 2005; 52: 212-18.
53. Camilleri RS, Mackie IJ, Humphries SE, Machin SJ, Cohen H. Lack of association of beta2-glycoprotein I polymorphisms Val247Leu and Trp316Ser with antiphospholipid antibodies in patients with thrombosis and pregnancy complications. Br J Haematol 2003; 120: 1066-72.
54. Sheng Y, Reddel SW, Herzog H, Wang YX, Brighton T, France MP, Robertson SA, Krilis SA. Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem 2001; 276: 13817-21.
55. Nimpf J, Wurm H, Kostner GM. Interaction of beta 2-glycoprotein-I with human blood platelets: influence upon the ADP-induced aggregation. Thromb Haemost 1985; 54: 397-401.
56. Schousboe I. Beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-91.
57. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, Barshack I, Kopolovic J, Shoenfeld Y. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999; 99: 2227-30.
58. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996; 5: 442-7.
59. Staub HL, Franck M, Ranzolin A, Norman GL, Iverson GM, von Mühlen CA. IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmun Rev 2006; 6: 104-6.
60. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004; 114: 593-5.
61. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus 2010; 19: 419-23.
62. Matsuura E, Lopez LR. Autoimmune-mediated atherothrombosis. Lupus 2008; 17: 878-87.
63. Beecken WD, Engl T, Ringel EM, Camphausen K, Michaelis M, Jonas D, Folkman J, Shing Y, Blaheta RA. An endogenous inhibitor of angiogenesis derived from a transitional cell carcinoma: clipped beta2-glycoprotein-I. Ann Surg Oncol 2006; 13: 1241-51.
64. 2-Glycoprotein I is proteolyically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999; 81: 87-95.
65. Passam FH, Qi JC, Tanaka K, Matthaei KI, Krilis SA. In vivo modulation of angiogenesis by beta 2 glycoprotein I. J Autoimmun 2010; 35: 232-40.
66. Beecken WD, Ringel EM, Babica J, Oppermann E, Jonas D, Blaheta RA. Plasmin-clipped beta(2)-glycoprotein-I inhibits endothelial cell growth by down-regulating cyclin A, B and D1 and up-regulating p21 and p27. Cancer Lett 2010; 296: 160-7.
67. Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, Palomo I, Harris EN, Meroni PL. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008; 34: 236-50.
68. 2-glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011; 117: 3453-9.
69. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011; DOI: .
70. Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A, Meroni PL. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495-500.
71. Satta N, Dunoyer-Geindre S, Reber G, Fish RJ, Boehlen F, Kruithof EK, de Moerloose P. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007; 109: 1507-14.
72. Sorice M, Longo A, Capozzi A, Garofalo T, Misasi R, Alessandri C, Conti F, Buttari B, Rigano R, Ortona E, Valesini G. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56: 2687-97.
73. Redecha P, Franzke CW, Ruf W, Mackman N, Girardi G. Neutrophil activation by the tissue factor/factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008; 118: 3453-61.
74. Di Simone N, Marana R, Castellani R, Di Nicuolo F, D'Alessio MC, Raschi E, Borghi MO, Chen PP, Sanguinetti M, Caruso A, Meroni PL. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum 2010; 62: 1504-12.
75. 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem 2003; 278: 33831-8.
76. Shi T, Giannakopoulos B, Yan X, Yu P, Berndt MC, Andrews RK, Rivera J, Iverson GM, Cockerill KA, Linnik MD, Krilis SA. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54: 2558-67.
77. Urbanus RT, Pennings MT, Derksen RH, de Groot PG. Platelet activation by dimeric beta(2)-glycoprotein I requires signalling via both glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost 2008; 6: 1405-12.
78. Kolyada A, Lee CJ, De Biasio A, Beglova N. A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome. PLoS ONE 2010; 5: e15345.
79. Andersson E, Rydengard V, Sonesson A, Morgelin M, Bjorck L, Schmidtchen A. Antimicrobial activities of heparin-binding peptides. Eur J Biochem 2004; 271: 1219-26.
80. 2-glycoprotein I is inhibited by protein H and M1 protein from Streptococcus pyogenes. Mol Microbiol 2007; 67: 482-92.
81. van der Poll T, Opal S. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8: 32-43.
82. Schultz H, Hume J, Zhang S, Gioannini TL, Weiss JP. A novel role for the bactericidal/permeability increasing protein in interactions of gram-negative bacterial outer membrane blebs with dendritic cells. J Immunol 2007; 179: 2477-84.
83. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ. Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 1429-31.
84. Schutt C, Schilling T, Grunwald U, Schonfeld W, Kruger C. Endotoxin-neutralizing capacity of soluble CD14. Res Immunol 1992; 143: 71-8.
85. Sadler JE. New concepts in von Willebrand disease. Annu Rev Med 2005; 56: 1702-91.
86. Hulstein JJ, Lenting PJ, de Laat B, Derksen RHWM, Fijnheer R, de Groot PG. Beta2-Glycoprotein I inhibits von Willebrand factor-dependent platelet adhesion and aggregation. Blood 2007; 110: 1483-91.
87. Schinco P, Borchiellini A, Tamponi G, Montaruli B, Garis G, Bazzan M, Pannocchia A, Modena V, Pileri A. Lupus anticoagulant and thrombosis: role of von Willebrand factor multimeric forms. Clin Exp Rheumatol 1997; 15: 5-10.
88. Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91: 1-19.
89. de Laat B, de Groot PG, Derksen RH, Urbanus RT, Mertens K, Rosendaal FR, Doggen CJ. Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood 2009; 114: 3656-61.
90. Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC, Giannakopoulos B, Hughes WE, Hogg PJ, Krilis SA. Redox control of β2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1. J Thromb Haemost 2010; 8: 1754-62.
91. Ganderton T, Berndt MC, Chesterman CN, Hogg PJ. Hypothesis for control of von Willebrand factor multimer size by intra-molecular thiol-disulphide exchange. J Thromb Haemost 2007; 5: 204-6.
92. Dayananda KM, Singh I, Mondal N, Neelamegham S. von Willebrand factor self-association on platelet GpIbalpha under hydrodynamic shear: effect on shear-induced platelet activation. Blood 2010; 116: 3990-8.
93. Yeh HC, Zhou Z, Choi H, Tekeoglu S, May W 3rd, Wang C, Turner N, Scheiflinger F, Moake JL, Dong JF. Disulfide bond reduction of von Willebrand factor by ADAMTS-13. J Thromb Haemost 2010; 8: 2778-88.
94. Price BE, Rauch J, Shia MA, Walsh MT, Lieberthal W, Gilligan HM, O'Laughlin T, Koh JS, Levine JS. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J Immunol 1996; 157: 2201-8.
95. Manfredi AA, Rovere P, Heltai S, Galati G, Nebbia G, Tincani A, Balestrieri G, Sabbadini MG. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum 1998; 41: 215-23.
96. Cheng HM. Physiologic apoptosis, beta 2-glycoprotein I, and antiphospholipid autoantibodies. Am J Obstet Gynecol 1996; 175: 1393.
97. Balasubramanian K, Chandra J, Schroit AJ. Immune clearance of phosphatidylserine-expressing cells by phagocytes. The role of beta2-glycoprotein I in macrophage recognition. J Biol Chem 1997; 272: 31113-17.
98. Balasubramanian K, Schroit AJ. Characterization of phosphatidylserine-dependent beta2-glycoprotein I macrophage interactions. Implications for apoptotic cell clearance by phagocytes. J Biol Chem 1998; 273: 29272-7.
99. Maiti SN, Balasubramanian K, Ramoth JA, Schroit AJ. Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members. J Biol Chem 2008; 283: 3761-6.
100. Reed JH, Giannakopou los B, Jackson MW, Krilis SA, Gordon TP. Ro 60 functions as a receptor for beta(2)-glycoprotein I on apoptotic cells. Arthritis Rheum 2009; 60: 860-9.
101. Nomura S, Komiyama Y, Matsuura E, Kokawa T, Takahashi H, Koike T. Binding of beta 2-glycoprotein I to platelet-derived microparticles. Br J Haematol 1993; 85: 639-40.
102. Abdel-Monem H, Dasgupta SK, Le A, Prakasam A, Thiagarajan P. Phagocytosis of platelet microvesicles and beta2-glycoprotein I. Thromb Haemost 2010; 104: 335-41.